The Food and Drug Administration (FDA) has approved Calquence® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,